Scott Alexander examines the development and effectiveness of vilazodone and vortioxetine, two antidepressants designed to work faster and better than SSRIs, but which ultimately failed to live up to expectations.

Scott reviews a paper proposing a computational model of mood and emotions based on predictive processing, discussing its implications for understanding mood disorders.

Scott reviews a theory about serotonin receptors that explains how they help cope with stress, and discusses its implications and limitations.

Scott Alexander critically examines pharmacogenomic testing for antidepressants, particularly the GeneSight test, expressing skepticism about its current effectiveness and validity.

Scott Alexander defends his stance on the 'chemical imbalance' theory of depression, arguing that Mad In America's critique actually supports his view of a more nuanced understanding in psychiatry.

Scott Alexander defends psychiatry's use of 'chemical imbalance' theory, arguing it was meant to emphasize depression's biological basis rather than claiming a simple serotonin deficiency.